Cargando…

Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma

Multiple myeloma (MM) is the second most common haematological malignancy and is an incurable disease of neoplastic plasma cells (PC). Newly diagnosed MM patients currently undergo lengthy genetic testing to match chromosomal mutations with the most potent drug/s to decelerate disease progression. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebert, Lisa M., Vandyke, Kate, Johan, M. Zahied, DeNichilo, Mark, Tan, Lih Y., Myo Min, Kay K., Weimann, Benjamin M., Ebert, Brenton W., Pitson, Stuart M., Zannettino, Andrew C. W., Wallington‐Beddoe, Craig T., Bonder, Claudine S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936512/ https://www.ncbi.nlm.nih.gov/pubmed/34245117 http://dx.doi.org/10.1002/1878-0261.13055

Ejemplares similares

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome
por: Tan, Lih Yin, et al.
Publicado: (2016)

A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis
por: Ebert, Lisa M., et al.
Publicado: (2016)

CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix
por: Martini, Carmela, et al.
Publicado: (2021)

Vasculogenic mimicry structures in melanoma support the recruitment of monocytes
por: Tan, Lih Y., et al.
Publicado: (2022)

Enhancing ER stress in myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Novel therapies for multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Desmoglein-2 is important for islet function and β-cell survival
por: Myo Min, Kay K., et al.
Publicado: (2022)

Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma
por: Zeissig, Mara N., et al.
Publicado: (2020)

PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma
por: Noll, Jacqueline E., et al.
Publicado: (2015)

Prognostic and predictive biomarker developments in multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2021)

Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies
por: Lewis, Alexander C., et al.
Publicado: (2018)

Author Correction: Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies
por: Lewis, Alexander C., et al.
Publicado: (2021)

Characterization of the role of Samsn1 loss in multiple myeloma development
por: Friend, Natasha L., et al.
Publicado: (2020)

SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma()()
por: Noll, Jacqueline E., et al.
Publicado: (2014)

Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?
por: Tan, Lih Yin, et al.
Publicado: (2017)

GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice
por: Friend, Natasha, et al.
Publicado: (2020)

Plant-derived soybean peroxidase stimulates osteoblast collagen biosynthesis, matrix mineralization, and accelerates bone regeneration in a sheep model
por: Barker, Alexandra J., et al.
Publicado: (2021)

DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment
por: Hewett, Duncan R., et al.
Publicado: (2017)

Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo
por: Zeissig, Mara N., et al.
Publicado: (2020)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
por: Bennett, Melissa K., et al.
Publicado: (2021)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

LCRF‐0006, a small molecule mimetic of the N‐cadherin antagonist peptide ADH‐1, synergistically increases multiple myeloma response to bortezomib
por: Mrozik, Krzysztof M., et al.
Publicado: (2020)

Bevacizumab-Induced Hypertension in Glioblastoma Patients and Its Potential as a Modulator of Treatment Response
por: Scheer, Kaitlin G., et al.
Publicado: (2023)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
por: Liapis, Vasilios, et al.
Publicado: (2017)

Dengue Virus-Induced Inflammation of the Endothelium and the Potential Roles of Sphingosine Kinase-1 and MicroRNAs
por: Aloia, Amanda L., et al.
Publicado: (2015)

Desmoglein 2 Is Less Important than Desmoglein 3 for Keratinocyte Cohesion
por: Hartlieb, Eva, et al.
Publicado: (2013)

Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy
por: Ebert, Lisa M, et al.
Publicado: (2020)

Desmoglein directs differentiation
por: Short, Ben
Publicado: (2009)

Desmogleins: Hair Perspective
por: Nigam, Pramod Kumar
Publicado: (2013)

A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties
por: Pitman, Melissa R., et al.
Publicado: (2015)

Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer
por: Barber, Alison G., et al.
Publicado: (2014)

Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo
por: Clark, Kimberley C., et al.
Publicado: (2020)

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo
por: Opperman, Khatora S., et al.
Publicado: (2019)

Desmoglein 2 mutant mice develop cardiac fibrosis and dilation
por: Krusche, Claudia A., et al.
Publicado: (2011)

Long-lasting Localized Pemphigus Vulgaris without Detectable Serum Autoantibodies Against Desmoglein 3 and Desmoglein 1
por: Yoshifuku, Asuka, et al.
Publicado: (2016)

E-cadherin binds to desmoglein to facilitate desmosome assembly
por: Shafraz, Omer, et al.
Publicado: (2018)

N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer
por: Mrozik, Krzysztof Marek, et al.
Publicado: (2018)

Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities
por: Myo Min, Kay K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fs4d2si9gak9p8te8lml9o3085